Nivolumab, a programmed cell death protein 1 (PD-1) inhibitor, has demonstrated significant clinical activity and improved survival outcomes in patients with advanced HNSCC [8, 9]. Here, PDCD1 is linked to head and neck squamous cell carcinoma.